WO2023002433 - COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING CORONAVIRUS VARIANT INFECTIONS AND METHODS OF USING THE SAME
National phase entry:
Publication Number
WO/2023/002433
Publication Date
26.01.2023
International Application No.
PCT/IB2022/056759
International Filing Date
21.07.2022
Title **
[English]
COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING CORONAVIRUS VARIANT INFECTIONS AND METHODS OF USING THE SAME
[French]
COMPOSITIONS ET VACCINS POUR LE TRAITEMENT ET/OU LA PRÉVENTION D'INFECTIONS À VARIANTS DE CORONAVIRUS ET MÉTHODES D'UTILISATION DE CEUX-CI
Applicants **
ENGENEIC MOLECULAR DELIVERY PTY LTD
Building 2, 25 Sirius Road
Lane Cove West
Sydney, New South Wales 2066, AU
Inventors
BRAHMBHATT, Himanshu
c/o ENGENEIC MOLECULAR DELIVERY PTY LTD
Building 2, 25 Sirius Road
Lane Cove West
Sydney, New South Wales 2066, AU
MACDIARMID, Jennifer
c/o ENGENEIC MOLECULAR DELIVERY PTY LTD
Building 2, 25 Sirius Road
Lane Cove West
Sydney, New South Wales 2066, AU
Priority Data
63/224,838
22.07.2021
US
17/480,073
20.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2058 | |
| EPO | Filing, Examination | 9270 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 4360 |
Total: 16881 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.[French]
La présente invention concerne des compositions et des méthodes servant au traitement, ainsi qu'à la vaccination contre des infections virales à SARS-CoV-2, y compris des infections virales à variants du SARS-CoV-2.